S&P 500 7,811.54 +0.59%Nasdaq 27,366.17 +0.64%Dow 51,654.95 +0.83%Russell 2000 2,806.98 +0.46%as of 2026-10-09 close
▚ The MicroCap Herald
Micro-cap and nano-cap intelligence, before the crowd
Uplistings & IPOs

First Phosphate Skips a Rung: ADR Uplisting Lands the LFP Developer on the Nasdaq Global Market

The Quebec-focused phosphate company moved its American Depositary Receipts from OTCQX to the Nasdaq Global Market on August 10 under the ticker PHOS — a cross-border listing route that raised no new capital and issued no new shares.
Illustrative photograph: US banknotes and coins.

A week after BioStem Technologies made the jump from over-the-counter trading to the Nasdaq Capital Market, another graduation came through — by a different door and onto a higher tier. First Phosphate Corp. began trading on the Nasdaq Global Market on Monday, August 10, under the ticker PHOS, uplisting its American Depositary Receipts from the OTCQX market, according to the company's announcement carried by StockTitan and The Globe and Mail.

First Phosphate is a Canadian mineral exploration and clean-technology company developing what it describes as a vertically integrated supply chain for lithium iron phosphate battery production in North America. Its flagship Bégin-Lamarche property in Quebec hosts igneous phosphate rock — a rare North American occurrence prized for high purity and low impurities relative to the sedimentary deposits that dominate global supply, per the announcement.

The mechanics are worth understanding because they differ from a conventional uplisting. First Phosphate's US presence runs through ADRs, each representing 10 common shares, administered by depositary bank BNY Mellon. With the Nasdaq listing, its Level 1 ADRs — the sponsored program that traded on OTCQX under FRSPF — converted automatically and at no cost to holders into Level 2 ADRs, the exchange-listed classification, per StockTitan. The OTCQX quotation was discontinued the same day, while the company's home listing on the Canadian Securities Exchange and its Frankfurt quotation continue unaffected. Shareholders can convert common shares into ADRs free of charge through December 31, 2026.

Notably, the transaction raised nothing. No new securities were issued and no capital came in the door, per StockTitan — the listing is purely a venue upgrade aimed at US institutional access, index eligibility and tighter trading. StockTitan data placed the company's market capitalization around $242.7 million with a float of roughly 160 million shares, putting First Phosphate near the top of the micro-cap band and helping explain how it qualified for the Nasdaq Global Market, whose initial listing standards on income, equity and float exceed those of the Capital Market tier where most former OTC companies land.

The listing also arrives on the heels of a modest but strategically relevant financing item: on August 5, the company announced approval of $4.84 million in non-repayable government contributions for road infrastructure and power transmission serving the project, per StockTitan. Like 5E Advanced Materials' EXIM investment this week, it is another data point in a 2026 pattern of public money de-risking early-stage critical-minerals development while equity markets watch.

The caveats are the standard ones for pre-production miners, plus a few specific to cross-listed structures. First Phosphate generates no revenue, and its valuation rests on resource development that requires years of additional permitting, engineering and financing. ADR structures add a layer of ratio math and depositary mechanics that can confuse retail order entry, and liquidity fragmented across Nasdaq, the CSE and Frankfurt can produce pricing gaps between venues.

Still, for the OTC ecosystem, the move extends this month's theme: the listing window remains open, and it is admitting more than one kind of company through more than one kind of door. BioStem took the conventional OTCQB-to-Capital-Market path at a $68 million valuation; First Phosphate arrived on the Global Market via ADR upgrade at more than three times that size. Both will now be judged on the same standard — whether exchange status actually delivers the institutional ownership it promises.

Sources & further reading

This article is for general information only and is not investment advice. Figures are as reported by the cited sources at time of writing.

Related coverage

Illustrative photograph: an industrial manufacturing facility.
Uplistings & IPOs

Chilwa Minerals Added a Nasdaq Listing With a US$3.5 Million ADS Offering at $5.60, Netting About US$2.5 Million for a Malawi Explorer Whose June 30 Cash Stood at A$1.1 Million

The ASX-listed Malawi heavy-mineral-sands explorer sold 625,000 American Depositary Shares with matching five-year warrants through Maxim Group, began trading as CHWM on Oct. 1 and closed Oct. 2. Its prospectus estimates about US$2.5 million net and flags going-concern doubt if more capital is not raised.

Imogen Farrow · October 10, 2026
Illustrative photograph: laboratory research equipment.
Uplistings & IPOs

Retension Pharmaceuticals Priced 3.75 Million Shares at $12.00 for Its Nasdaq Debut, Upsized From 3.3 Million, With a Going-Concern Paragraph in Its Audit and One Drug in Phase 2b

The Falls Church, Virginia hypertension-drug developer priced at the midpoint of its $11-$13 range and lifted the share count, for about $38.9 million net. Its prospectus discloses $13.5 million of cash at June 30, a going-concern qualification on the 2025 audit and no product revenue.

Imogen Farrow · October 10, 2026
Illustrative photograph: a retail store interior.
Uplistings & IPOs

Greene Concepts' Regulation A Amendment Was Qualified Sept. 30; Five Days Later It Priced the Remaining Units at $0.0025 a Share, Below Both Its Oct. 2 Close of $0.011 and Its Own Stated Book Value of $0.06

The OTCID-quoted bottler, which completed a 1-for-80 reverse split on July 30, is offering up to 2,357,500 units of 100 shares each for $589,375 in gross proceeds under Tier 1 of Regulation A. The circular reports $29,552 of cash at April 30, substantial doubt about going-concern status, and 6 billion shares that could be issued on conversion of 60 Series B preferred shares.

Imogen Farrow · October 10, 2026